GTG Labs (GENE): Net earnings per share (EPS TTM)

gtglabs.com - graphic logo of issuer GENE

High regulatory barriers and patents protect the position of Genetic Technologies (GENE). Revenues are based on the sale of genomic tests for the early detection of cardiological and oncological pathologies. The annual net income per share trend demonstrates financial stability, with the indicator remaining around -1.82. Growth potential persists due to the global medical shift toward preventive diagnostics.

GENE GTG Labs Net earnings per share for the last four quarters (07/04/2022 - 10/26/2024)

Analytical breakdowns and data insights for company Genetic Technologies Ltd (GENE)

- current quotes and average value forecast:
Price Chart GTG Labs|GENE - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization Genetic Technologies Limited|GENE - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Genetic Technologies|GENE - Book Valuation of Business|Market Capitalization to Book Value Ratio gtglabs.com|GENE - Company Balance Sheet Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Genetic Technologies|GENE - Long-Term Liabilities to Capital|Short-Term Debt to Equity GTG Labs|GENE - Company Aggregate Debt|Debts to Book Capitalization Genetic Technologies Limited|GENE - Long-Term Debt|Company Current Liabilities Genetic Technologies|Quick Ratio gtglabs.com
- earnings and multiples data:
GENE - Net Financial Result|Projected Future Earnings Genetic Technologies|GENE - Price to Earnings Ratio|Projected Price to Earnings GTG Labs|GENE - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Genetic Technologies Limited|GENE - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Genetic Technologies|GENE - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth gtglabs.com|GENE - Net earnings per share growth this year|Earnings growth forecast for next year Genetic Technologies
Fundamental valuation:gtglabs.com (GENE)
Manufactured products of GTG Labs

This metric is calculated by dividing the total annual net income by the total number of outstanding shares. This figure separates the actual intrinsic value of the business from market speculation. For Genetic Technologies (GENE), stable demand for cancer diagnostics ensures the predictability of this value. An investor can assess the resilience of this defensive healthcare asset through the company's net income per share over 12 months. This chart's price action reveals the real capitalization potential.

Main competitors

A - Earnings per share for the last twelve months|Net earnings per share for the last four quarters questdiagnostics.com DGX|ILMN: Net earnings per share (EPS TTM)|EXAS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months PerkinElmer|Bio-Rad Corp (BIO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) NNNN|soterahealth.com (SHC) - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) QDEL (QuidelOrtho Corporation)|OPKO Health Inc (OPK) - Net earnings per one share for the last twelve months|CDNA - Earnings per share for the last twelve months|MRVI (Maravai) - Earnings per share for the last 12 months|FLGT: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months fluidigm.com (LAB)|Net earnings per share for the last 12 months CTKB|OSUR (OraSure Technologies, Inc.) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) XGN|Net earnings per share for the last four quarters MDxHealth, Inc.|Net earnings per share (EPS TTM) LUCD (Lucid Diagnostics Inc.)|PRE - Net earnings per share for the last 12 months|IMDX: Net earnings per share for the last 12 months|Earnings per share for the trailing year TRIB (Trinity Biotech plc)|PRPH (ProPhase) - Net earnings per share for the last 12 months|AIMD: Earnings per share for the last four quarters|CODX (Co-Diagnostics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months heartsciences.com HSCS|Net earnings per share (EPS TTM) BMRA|Net earnings per share for the last 12 months cardiodiagnosticsinc.com CDIO|Net earnings per share (EPS TTM) ONCO (Onconetix Corp)|Earnings per share for the trailing year VRAX|BJDX - Earnings per share for the last twelve months|AWH (aspirawh.com) - Earnings per share for the last 12 months|Accelerate Diagnostics, Inc. (AXDX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months centogene.com (CNTG)|Earnings per share for the last twelve months Enzo Biochem Inc.|Earnings per share for the last twelve months FRES|Earnings per share for the last twelve months 23andMe Holding Co. (ME)|PMD - Net earnings per one share for the last twelve months